Functional Evaluation After Maxillectomy and Scapular Free Flap Reconstruction

March 5, 2025 updated by: SAYAH Charline, Hôpital de la Croix-Rousse

Total or Subtotal Maxillectomy with Scapular Free Flap Reconstruction: Airway Management, Aesthetic and Functional Results

The goal of the study is to analyse the functional and aesthetic outcomes after removal of the maxillar bone and reconstruction with part of the scapular bone for people having maxillary tumor

Study Overview

Status

Completed

Study Type

Observational

Enrollment (Actual)

16

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Lyon, France, 69004
        • Croix Rousse Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

all patients with malignant or benign maxillary sinus tumors managed by total maxillectomy and free scapula tip flap reconstruction between January 2015 and July 2023 in the Ear-Nose-Throat (ENT) department of Croix Rousse Hospital in Lyon, France.

Description

Inclusion Criteria:

  • Patient with maxillary sinus tumor
  • Treated by maxillectomy with free scapula tip flap reconstruction
  • 18 years of age or older

Exclusion Criteria:

  • Reconstruction failure
  • Carcinomatous recurrence and/or further progression impacting quality of life
  • Death

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
patients studied
patients with malignant or benign maxillary sinus tumors managed by total maxillectomy and free scapular flap reconstruction

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
time to resumption of oral feeding
Time Frame: through study completion, an average of 15 days
time to resumption of oral feeding after the surgery, measuring in days
through study completion, an average of 15 days
duration of hospitalization in a continuing care unit
Time Frame: through study completion, an average of 15 days
hospitalization in a continuing care unit after the surgery, measuring in days
through study completion, an average of 15 days
Tracheotomy
Time Frame: through study completion, an average of 15 days
need to do a tracheotomy during or after the surgery, qualitative outcome (yes or no)
through study completion, an average of 15 days
Hospitalisation time
Time Frame: through study completion, an average of 15 days
Duration of the whole hospitalisation in the ENT unit, measuring in days
through study completion, an average of 15 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Swallowing assessment with the Functional Oral Intake Scale
Time Frame: through study completion, an average of 2 years
Swallowing was assessed using the Functional Oral Intake Scale (FOIS). Scores ranged from one (no oral intake) to seven (normal diet with no change in texture), with a high score indicating good swallowing function.
through study completion, an average of 2 years
Aesthetic evaluation
Time Frame: through study completion, an average of 2 years
A subjective patient assessment of the aesthetic result was carried out using the appearance subcategory of the University of Washington Quality of Life Questionnaire (UW-QOL v4). There are five possible responses, each scored at 0, 25, 50, 75 and 100. A score of 0 represents the worst possible aesthetic result, and a score of 100 the best possible result.
through study completion, an average of 2 years
Quality of Life assessment using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (version 3.0) and European Organisation for Research and Treatment of Cancer Head & Neck 43 questionnaires.
Time Frame: through study completion, an average of 2 years

The QLQ-C30 is a general quality-of-life questionnaire specific to oncological pathology and intended for all cancer patients regardless of location.

It comprises a central questionnaire for assessing 5 functions (physical, cognitive, social, limitations in daily activities and psychological), 9 symptoms and overall health. To this questionnaire can be added modules specific to a cancer site, such as the EORTC QLQ-H&N43 for head and neck cancers.

Responses to both questionnaires are then transformed to produce a score ranging from 0 to 100. For the functional scales and the global health scale, a high score represents a good level of functioning, while a high score on the symptom scales indicates a high level of symptoms and/or problems.

through study completion, an average of 2 years
Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire
Time Frame: through study completion, an average of 2 years
Functional assessment of the upper limb was performed using the Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire. This is a subjective self-assessment questionnaire of the overall functional capacity of both upper limbs. The score ranges from 0 to 100. Higher scores indicate an inability to perform tasks, great difficulty in doing them, or significant symptoms.
through study completion, an average of 2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Carine FUCHSMANN, Hospice Civil de Lyon

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2023

Primary Completion (Actual)

March 1, 2023

Study Completion (Actual)

June 30, 2023

Study Registration Dates

First Submitted

February 18, 2025

First Submitted That Met QC Criteria

March 5, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

March 5, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Maxillary Sinus Squamous Cell Carcinoma

Subscribe